kabutan

STELLA PHARMA CORPORATION(4888) Summary

4888
TSE Growth
STELLA PHARMA CORPORATION
519
JPY
-21
(-3.89%)
Apr 28, 3:30 pm JST
3.26
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
509
Apr 28, 11:20 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.74
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
535 JPY 3.35 USD
Previous Close Apr 27
540 JPY 3.38 USD
High Apr 28, 9:02 am
552 JPY 3.46 USD
Low Apr 28, 3:02 pm
510 JPY 3.20 USD
Volume
754,500
Trading Value
0.40B JPY 2.49M USD
VWAP
526.09 JPY 3.3 USD
Minimum Trading Value
51,900 JPY 326 USD
Market Cap
0.02T JPY 0.11B USD
Number of Trades
1,478
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
1,514
1-Year High Mar 25, 2026
27,213
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 2,853,200
Apr 17, 2026 9,600 2,371,100 246.99
Apr 10, 2026 500 2,221,600 4443.20
Apr 3, 2026 0 2,002,900
Mar 27, 2026 14,600 2,595,700 177.79
Company Profile
STELLA PHARMA CORPORATION is a subsidiary of Stella Chemifa. The company develops, manufactures, and sells boron-based pharmaceuticals for cancer radiotherapy.
Sector
Pharmaceuticals
STELLA PHARMA CORPORATION is a biotech venture company within the Stella Chemifa group. It specializes in the development, manufacturing, and sales of "Steboronine," a boron-based pharmaceutical for cancer radiotherapy. The company has obtained the world's first approval for a drug used in Boron Neutron Capture Therapy (BNCT). Steboronine has been launched in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. Clinical trials are currently underway to expand its applications to recurrent malignant glioma and recurrent high-grade meningioma. Leveraging its strength in high-purity boron-10 enrichment technology, STELLA PHARMA CORPORATION aims to expand its business both domestically and internationally.